Gene · 2696
Papers1,380
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,380
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Interaction between fatty pancreas disease and genetically predicted glucose-dependent insulinotropic polypeptide on incident type 2 diabetes: evidence from the UK Biobank. | Front Endocrinol (Lausanne) | 2026 | 42339085 | PubTator, text mining | PubMed |
| Engineering single-dose plasmid DNA for sustained in vivo delivery of designer incretins. | Trends Biotechnol | 2026 | 42321077 | PubTator, text mining | PubMed |
| Glucagon-like peptide-1 agonists usage to widen the living donor pool for liver transplantation: A novel metabolic strategy. | World J Transplant | 2026 | 42281856 | PubTator, text mining | PubMed |
| Tirzepatide in type 1 diabetes: beyond mere weight loss. | Expert Rev Clin Pharmacol | 2026 | 42240053 | PubTator, text mining | PubMed |
| Beyond weight loss: How metabolism in human adipocytes is shaped by GLP-1R agonists and dual GIPR/GLP-1R agonists. | Pharmacol Res | 2026 | 42229677 | PubTator, text mining | PubMed |
| Target Perturbation of Genetically Proxied Antidiabetic Drug Targets and Pneumonia Risk: A Mendelian Randomization Analysis. | Curr Top Med Chem | 2026 | 42227366 | PubTator, text mining | PubMed |
| Hypercalcemia Induced by Tirzepatide and Calcium Supplementation: A Case Report. | Cureus | 2026 | 42226819 | PubTator, text mining | PubMed |
| Multivalent antibody-based conjugates as new tools for tailored modulation of G protein-coupled receptors. | Br J Pharmacol | 2026 | 42225334 | PubTator, text mining | PubMed |
| A Hydrophobic Tag-Assisted Liquid-Phase Strategy for the Synthesis of Retatrutide. | Org Lett | 2026 | 42224238 | PubTator, text mining | PubMed |
| Searching for New Pharmacological Treatments of Alcohol Use Disorder (AUD): Focus on GLP-1 Receptor Agonists. | Int J Mol Sci | 2026 | 42196481 | PubTator, text mining | PubMed |
| The Paradox and Future of GLP-1/GIP Combination Therapies: Efficacy and Mechanisms. | Annu Rev Nutr | 2026 | 42166683 | PubTator, text mining | PubMed |
| Novel Dihydroisoquinolinone-Amide Compounds as GIPR Agonists for Treating Type 2 Diabetes Mellitus and Obesity. | ACS Med Chem Lett | 2026 | 42157820 | PubTator, text mining | PubMed |
| Amping Up Receptor Balance and Bias: Fine Tuning of Unimolecular Multiagonists. | J Med Chem | 2026 | 42152230 | PubTator, text mining | PubMed |
| Innovations in Obesity Treatment: Beyond Adipose Tissue Dysfunction. | Obes Rev | 2026 | 42144264 | PubTator, text mining | PubMed |
| Harnessing PPAR pharmacology through dual incretin-directed delivery. | Cell Metab | 2026 | 42102815 | PubTator, text mining | PubMed |
| Assessing the Impact of Glucagon-like Peptide-1 and Glucagon-like Peptide-1/glucose-dependent Insulinotropic Polypeptide Receptor Agonist Shortages on Glycemic Control: A Single Center Study. | J Pharm Pract | 2026 | 42084545 | PubTator, text mining | PubMed |
| Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. | Pharmaceutics | 2026 | 42076099 | PubTator, text mining | PubMed |
| Identification of key genes in recurrent pregnancy loss related to obesity. | Gynecol Endocrinol | 2026 | 42013197 | PubTator, text mining | PubMed |
A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity. | Diabetes Obes Metab | 2026 | 42010360 | PubTator, text mining | PubMed |
| Tirzepatide improves angiogenesis after diabetic hindlimb ischemia through Akt/eNOS and ERK1/2 pathways. | Peptides | 2026 | 42002077 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2696/papers?page=3